Attached files
| file | filename |
|---|---|
| EX-10.12 - EX-10.12 - Janux Therapeutics, Inc. | d143369dex1012.htm |
| EX-10.11 - EX-10.11 - Janux Therapeutics, Inc. | d143369dex1011.htm |
| EX-10.10 - EX-10.10 - Janux Therapeutics, Inc. | d143369dex1010.htm |
| EX-10.9 - EX-10.9 - Janux Therapeutics, Inc. | d143369dex109.htm |
| EX-10.8 - EX-10.8 - Janux Therapeutics, Inc. | d143369dex108.htm |
| EX-10.7 - EX-10.7 - Janux Therapeutics, Inc. | d143369dex107.htm |
| EX-10.6 - EX-10.6 - Janux Therapeutics, Inc. | d143369dex106.htm |
| EX-10.2 - EX-10.2 - Janux Therapeutics, Inc. | d143369dex102.htm |
| EX-10.1 - EX-10.1 - Janux Therapeutics, Inc. | d143369dex101.htm |
| EX-4.2 - EX-4.2 - Janux Therapeutics, Inc. | d143369dex42.htm |
| EX-3.4 - EX-3.4 - Janux Therapeutics, Inc. | d143369dex34.htm |
| EX-3.3 - EX-3.3 - Janux Therapeutics, Inc. | d143369dex33.htm |
| EX-3.2 - EX-3.2 - Janux Therapeutics, Inc. | d143369dex32.htm |
| EX-3.1 - EX-3.1 - Janux Therapeutics, Inc. | d143369dex31.htm |
| S-1 - S-1 - Janux Therapeutics, Inc. | d143369ds1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated April 16, 2021 in the Registration Statement (Form S-1) and related Prospectus of Janux Therapeutics, Inc. dated May 19, 2021 for the registration of shares of its common stock.
/s/ Ernst & Young LLP
San Diego, California
May 19, 2021